Author pages are created from data sourced from our academic publisher partnerships and public sources.
Share This Author
Natural history of progression after PSA elevation following radical prostatectomy.
Several clinical parameters help predict the outcomes of men with PSA elevation after radical prostatectomy, and these data may be useful in the design of clinical trials, the identification of men for enrollment into experimental protocols, and counseling men regarding the timing of administration of adjuvant therapies. Expand
Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer.
Novel forms of AR alteration that are prevalent in HRPC are reported, suggesting a novel mechanism for the development of HRPC that warrants further investigation and may be explored as potential biomarkers and therapeutic targets for advanced PCa. Expand
Natural History of Progression After PSA Elevation Following Radical Prostatectomy
Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy.
Clinical parameters can help risk stratify patients for prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy to enroll them in early aggressive treatment trials, and highlight that survival in low-risk patients can be quite prolonged. Expand
Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium.
The probability of organ-confined disease improved across the groups, and further stratification of the Gleason score and PSA level allowed better differentiation of individual patients. Expand
Genome-wide association study identifies a second prostate cancer susceptibility variant at 8q24
A second genetic variant in the 8q24 region that, in conjunction with another variant recently discovered, accounts for about 11%–13% of prostate cancer cases in individuals of European descent and 31% of cases in African Americans is reported. Expand
Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial.
Use of the percentage of free PSA can reduce unnecessary biopsies in patients undergoing evaluation for prostate cancer, with a minimal loss in sensitivity in detecting cancer. Expand
The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer.
From these analyses probability plots and nomograms have been constructed to assist urologists in the preoperative prediction of final pathological stage for patients with clinically localized prostate cancer. Expand
Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update.
Clinicians can use these nomograms when counseling individual patients regarding the probability of their tumor being a specific pathological stage to enable patients and physicians to make more informed treatment decisions based on the probabilities of a pathological stage, as well as risk tolerance and the values they place on various potential outcomes. Expand
Germline mutations in HOXB13 and prostate-cancer risk.
- C. Ewing, A. Ray, +22 authors K. Cooney
- Biology, Medicine
- The New England journal of medicine
- 11 January 2012
The novel HOXB13 G84E variant is associated with a significantly increased risk of hereditary prostate cancer, and this finding has implications for prostate-cancer risk assessment and may provide new mechanistic insights into this common cancer. Expand